Virus linked with prostate cancer
New microarray technology has linked a previously unknown virus to prostate cancer, although the exact relation between the virus and prost ate cancer is not yet clear. The virus, tentatively named XMRV, is similar to leukaemia viruses that infect mice, but seems to infect only human beings. The lack of studies in animals will complicate eff orts to determine the virus' precise role in prostate cancer, says Eric Klein, (Cleveland Clinic, Cleveland, OH, USA) who reported the study at the American Society for Clinical Oncology Prostate Cancer Symposium (San Francisco, CA, USA; Feb 24-26, 2006) . "Identifying the agent does not imply you have identifi ed causality", cautions Joseph DeRisi (University of California, San Francisco, CA, USA). "Proving causality could take many more years." DeRisi and colleagues created the virus chip used in the study. The same microarray was used to identify a new coronavirus that causes severe acute respiratory syndrome. Furthermore, the chip is a tool that can be used to invest igate any disease of unknown aetiology, especially when the epid em iol ogy of a disease suggests infec tion is a factor, says DeRisi.
Virus was seen in tissues from patients with prostate cancer who were homozygous for a single nucleotide polymorphism, known as R462Q, which codes for a variant, malfunctioning form of RNase L. These men are at substant ially increased risk of prostate cancer. According to Klein, about 15% of the population have this variant. It is associated with about 13% of prostate cancer, he adds, making it the most common gene variant linked to any human cancer. The wildtype enzyme degrades single-strand ed RNA in response to interferon or viral infection, preventing propaga tion of viruses once they have infected the cell, and trigg ering apoptosis in the host cell.
The chip contains several thousand conserved sequences from every virus known to infect plants, animals, and humans-a total of nearly 1000 viruses. Researchers use these sequences as probes to uncover previously unknown viruses in tissues.
The researchers are also attempting to identify other viruses in cancersparticularly those that occur in patients with compromised immune systems. These include AIDS-related lymph omas and skin cancers associated with solidorgan transplantation.
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Sentinel-node mapping for staging of colorectal cancer
Use of sentinel-node mapping to stage colorectal cancer can lead to increased detection of nodal metastases and lower recurrence compared with conventional procedures, according to new fi ndings (Am J Surg 2006; 191: 305-10).
Lymph-node status is one of the most important prognostic factors used to determine treatment after a diagnosis of colorectal cancer. Patients with nodal disease are given adjuvant chemotherapy because of evidence of potential mortality red uctions of 33% with such treatment; but there is no defi nitive evidence for survival benefi t with adjuvant chemo therapy in patients who are node-negative .
Because conventional pathology under stages 15-20% of patients with colo rectal cancer, sentinel-lymph-node map ping was developed to identify nodes most likely to harbour metastases. "It would be cost prohib itive to perform such ultra staging methods on all nodes harvested during conventional surg ery", says Sukamal Saha (Michigan State University, MI, USA).
Saha and co-workers compared outcomes of 500 consecutive patients who underwent sent inel-lymph-node mapping with 368 consecutive patients who underwent conventional surgery and pathological assessment.
Nodal positivity was 48% for the group assigned sentinel-lymph-node map ping, compared with 35% for the group assigned conventional staging (p<0·001). After a minimum of 2 years' follow-up, patients assigned nodal mapping (n=153) had an overall recur rence of 7%, compared with 25% for the 162 patients assigned conven tional staging (p=0·001).
Sentinel-node biopsy in colorectal cancer is controversial-studies have found identifi cation rates of 77-99%, resulting in a false-negative rate of 3-60%. "The diff erence in [this] study was that surgeons had [done] many more procedures. The volume of dye they injected was according to the diameter of the tumour as opposed to a fi xed volume [as] in other studies", says Markus Zuber (University of Basel, Switzerland). He adds that sentinelnode biopsy should be regarded as an investigational procedure until a randomised study is done.
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